A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
safety
over the course of study
Judy H Chiao, MD
Study Director
Cyclacel Pharmaceuticals, Inc.
United States: Food and Drug Administration
CYC116-06-01
NCT00560716
June 2007
November 2009
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |
South Texas Accelerated Research Therapeutics | San Antonio, Texas 78229 |